Abstract:Background. Osteoporosis is a systemic bone disease characterized by reduction of bone content. Bisphosphonates are first-line treatments for osteoporosis, but they have variable effectiveness. Genetic factors may explain these differences. The NF-κB signaling pathway plays a key role in the regulation of bone metabolism. We aimed to determine whether genetic variations in the NF-κB signaling pathway affect the effectiveness of alendronate in postmenopausal Chinese women with low bone mass. Methods. We recruited 455 postmenopausal Han Chinese women with primary osteoporosis or osteopenia aged 48–90 yrs who had experienced no spontaneous menses for at least 1 yr. All participants had dual X-ray absorptiometry (DEXA) bone mineral density (BMD) measurement at baseline and 1 yr after treatment. Treatment involved 1 yr administration of 70 mg oral alendronate weekly and 600 mg calcium and 125 IU of vitamin D daily. Thirteen tagSNPs in NF-κB1 (rs28362491, rs3774937, rs230521, rs230510, and rs4648068), RELA (rs7119750, rs11820062), and NLRC5 (rs289747, rs1566439, rs1684575, rs289726, rs289723, and rs41383) were chosen from the NCBI Locus Link and HapMap and genotyped individually. Genetic variation in these genes and the corresponding therapeutic response to alendronate treatment were analyzed. Results. Among the 13 tagSNPs, rs289747 was significantly correlated with the BMD change rate at the femoral neck ( P = 0.048 ). This significance no longer existed after Bonferroni correction. We then performed principal component analysis (PCA) and found NLRC5 (rs289747 and rs1566439) were strongly correlated with alendronate efficacy in femoral phenotypes and were major components of BMD change values, particularly total hip and intertrochanteric phenotypes. Furthermore, the PLINK linear regression GLM model revealed that haplotype TT of RELA (rs7119750 and rs11820062) and ICCTA of NF-κB1 (rs28362491, rs3774937, rs230521, rs230510, and rs4648068) were associated with BMD of the total hip among each haplotype after 1 yr of treatment. Conclusion. The NF-κB1, RELA, and NLRC5 genetic variations affect the therapeutic response of alendronate treatment for postmenopausal osteoporosis.

SOST Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Osteoporosis.

Lrp5 Polymorphisms and Response to Alendronate Treatment in Chinese Postmenopausal Women with Osteoporosis

Association Between Geranylgeranyl Pyrophosphate Synthase Gene Polymorphisms and Bone Phenotypes and Response to Alendronate Treatment in Chinese Osteoporotic Women

OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.

Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.

[Osteoprotegerin Gene Polymorphism and Therapeutic Response to Alendronate in Postmenopausal Women with Osteoporosis].

Association Between CTSK Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density.

SAA1 Gene Polymorphisms in Osteoporosis Patients

PFN1 Gene Polymorphisms and the Bone Mineral Density Response to Alendronate Therapy in Postmenopausal Chinese Women with Low Bone Mass

Genetic Polymorphisms in the Mevalonate Pathway Affect the Therapeutic Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density.

Association Between NF-κB Signal Pathway-Related Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density

The Therapeutic Response to Alendronate in Chinese Postmenopausal Women with Osteoporosis and the AluⅠ Polymorphism of Estrogen Receptor Β Gene

Pgpm_a_344818 1669..1678

Associations of Serum Osteocalcin and Polymorphisms of the Osteocalcin Gene with Bone Mineral Density in Postmenopausal and Elderly Chinese Women.

Analysis of Recently Identified Osteoporosis Susceptibility Genes in Han Chinese Women.

Genetic Polymorphisms of Nuclear Factor-B Family Affect the Bone Mineral Density Response to Zoledronic Acid Therapy in Postmenopausal Chinese Women

The Influence of Lys3Asn Polymorphism in the Osteoprotegerin Gene on Bone Mineral Density in Chinese Postmenopausal Women

Effectiveness of Alendronate in Treating Osteoporosis and Its Relationship with N740N Polymorphism of Low-density Lipoprotein Receptor Related Protein 5 Gene

Contribution of the Sclerostin Domain-Containing Protein 1 (SOSTDC1) Gene to Normal Variation of Peak Bone Mineral Density in Chinese Women and Men

Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.

Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment